Free tool
FAERS Monitor: Recarbrio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212819 or its brand name (Recarbrio, Cilastatin Sodium, Imipenem, Relebactam). Reports on generic versions are filed under their own applications.
Reports
92
Serious
75
82% of reports
Hospitalization
14
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use18
- death14
- product use in unapproved indication9
- pathogen resistance8
- drug ineffective6
- cardio-respiratory arrest5
- generalised tonic-clonic seizure5
- overdose5
- epilepsy4
- renal impairment4
- therapy non-responder4
- condition aggravated3
- extradural abscess3
- incorrect dose administered3
- incorrect product administration duration3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2021 | 16 |
| 2022 | 19 |
| 2023 | 21 |
| 2024 | 17 |
| 2025 | 12 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| extradural abscessSignal | 3 | 877.9 | 287.8 | 1,817 |
| pathogen resistanceSignal | 8 | 200.8 | 103.5 | 1,397 |
| generalised tonic-clonic seizureSignal | 5 | 69.1 | 29.5 | 271 |
| incorrect product administration durationSignal | 3 | 31.7 | 10.4 | 61 |
| epilepsySignal | 4 | 29.9 | 11.5 | 85 |
| cardio-respiratory arrestSignal | 5 | 27.3 | 11.7 | 102 |
| therapy non-responderSignal | 4 | 20.3 | 7.8 | 56 |
| renal impairmentSignal | 4 | 10.9 | 4.2 | 27 |
| product use in unapproved indicationSignal | 9 | 8.3 | 4.5 | 51 |
| overdoseSignal | 5 | 5.3 | 2.3 | 14 |
| off label useSignal | 18 | 4.7 | 3.1 | 51 |
| deathSignal | 14 | 3.7 | 2.3 | 26 |
| incorrect dose administered | 3 | 3.0 | 1.0 | 2 |
| condition aggravated | 3 | 2.3 | 0.7 | 1 |
| drug ineffective | 6 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.